Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

UBS Upgrades Insulet to Buy, Raises Price Target to $400

Author: Benzinga Newsdesk | November 19, 2025 07:26am
UBS analyst Danielle Antalffy upgrades Insulet (NASDAQ:PODD) from Neutral to Buy and raises the price target from $355 to $400.

Posted In: PODD

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist